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High aldehyde dehydrogenase (ALDHhi) activity has been reported in normal and cancer
stem cells. We and others have shown previously that human ALDHhi cardiac atrial
appendage cells are enriched with stem/progenitor cells. The role of ALDH in these cells
is poorly understood but it may come down to the specific ALDH isoform(s) expressed.
This study aimed to compare ALDHhi and ALDHlo atrial cells and to identify the isoform(s)
that contribute to ALDH activity, and their functional role.
Methods and Results: Cells were isolated from atrial appendage specimens from
patients with ischemic and/or valvular heart disease undergoing heart surgery. ALDHhi
activity assessed with the Aldefluor reagent coincided with primitive surface marker
expression (CD34+). Depending on their ALDH activity, RT-PCR analysis of ALDHhi and
ALDHlo cells demonstrated a differential pattern of pluripotency genes (Oct 4, Nanog)
and genes for more established cardiac lineages (Nkx2.5, Tbx5, Mef2c, GATA4). ALDHhi
cells, but not ALDHlo cells, formed clones and were culture-expanded. When cultured
under cardiac differentiation conditions, ALDHhi cells gave rise to a higher number
of cardiomyocytes compared with ALDHlo cells. Among 19 ALDH isoforms known in
human, ALDH1A3 was most highly expressed in ALDHhi atrial cells. Knocking down
ALDH1A3, but not ALDH1A1, ALDH1A2, ALDH2, ALDH4A1, or ALDH8A1 using siRNA
decreased ALDH activity and cell proliferation in ALDHhi cells. Conversely, overexpressing
ALDH1A3 with a retroviral vector increased proliferation in ALDHlo cells.
Conclusions: ALDH1A3 is the key isoform responsible for ALDH activity in ALDHhi atrial
appendage cells, which have a propensity to differentiate into cardiomyocytes. ALDH1A3
affects in vitro proliferation of these cells.
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INTRODUCTION
In many studies, putative cardiac-resident stem and progenitor
cells were isolated based on the expression of hematopoietic stem
cell (HSC) markers, such as CD34, stem cell antigen-1 (Sca-1),
and c-kit/CD117 (1–3). However, no single cell surface marker
definitely identifies a specific entity of cardiac stem cells (4).
Therefore, “functional” stem cell markers have been intensively
searched for. It has been proposed that, irrespective of their
lineage origin, stem cells may respond in similar ways to regulate
self-renewal and differentiation, and that putative “stemness”
genes may serve as universal stem cell markers (5). A widely used
universal stem cell marker is aldehyde dehydrogenase (ALDH)
(6–8). In tunicates, few pluripotential cells with high ALDH
enzymatic activity (ALDHhi) were able to give rise to all somatic
and reproductive cell lineages (9).
ALDH is a generic designation for a superfamily of NAD-
dependent enzymes that catalyze the oxidation of aldehydes to
acids. The ALDH family includes 19 members in human, which
share some amino acid sequence similarity and certain functions
while differing in intracellular localization, tissue distribution,
and substrate specificity. ALDHs are localized in the cytoplasm,
mitochondria or nucleus and participate in many biological
processes including the detoxification of exogenous aldehydes
and the metabolism of vitamin A, alcohol and reactive oxygen
species (ROS) (7, 10). ALDH1A1 is a detoxifying enzyme
responsible for oxidizing aldehydes to carboxylic acids (11).
High-level ALDH1A1 expression regulates self-renewal and
differentiation in HSCs and neural stem cells (12–14). ALDH1A1
has been implicated in chemotherapeutic resistance of HSCs
via metabolization and detoxification of chemotherapeutics like
cyclophosphamide (15). ALDH1A is the rate-limiting factor
in the production of retinoic acid (RA) via oxidation of all-
trans retinal and 9-cis-retinal (16–18). RA activates nuclear RA
receptors (RARs) that control the transcription of genes with
RA response elements (RAREs) in their promoters, thereby
regulating stem cell functions (13, 19). Elevated activity of
additional ALDH isoforms, namely ALDH1A2, ALDH1A3,
ALDH1A7, ALDH2∗2, ALDH3A1, ALDH4A1, ALDH5A1,
ALDH6, andALDH9A1, has been observed in normal and cancer
stem cells (10, 20–25). It has been proposed that the role of ALDH
as a stem cell marker may come down to the specific isoform(s)
expressed (20). Thus, ALDH not only may be considered a
stem cell marker, but also may well play functional roles in
terms of self-renewal, differentiation, and/or expansion. It should
be noted, however, that currently available commercial assays
identifying ALDHhi cells as those actively metabolizing BODIPY-
aminoacetaldehyde (Aldefluor R©) (26) do not distinguish the
specific ALDH isoforms (8).
In human, ALDH expression by HSCs has been evaluated
as a predictor of hematopoietic recovery after peripheral stem
cell mobilization (27) and a biomarker for umbilical cord
blood potency (28). Both bone marrow and cord blood-derived
ALDHhi cells have shown therapeutic potential in limb ischemia
(29) and myocardial infarction models (30). In clinical trials,
autologous bone marrow-derived ALDHhi cells did not improve
functional or magnetic resonance outcomes in patients with
peripheral artery disease (31). More encouraging results were
reported in patients with ischemic heart failure (32). We were
the first to isolate cardiac atrial appendage-derived progenitor
cells based on ALDH activity (33, 34). Koninckx et al. (35) then
reported that human ALDHhi cardiac atrial appendage stem cells
(CASC) gave rise to cardiac cells and improved cardiac function
upon injection into infarcted pig hearts. However, this study
did not compare ALDHhi and ALDHlo cells nor did it define
the specific ALDH isoform(s) expressed and their functional
roles.
The present study aimed to compare human ALDHhi
and ALDHlo atrial appendage cells both phenotypically and
functionally, and to identify the specific ALDH isoform(s)
expressed. ALDH1A3 was found to be the key isoform
responsible for Aldefluor positivity in ALDHhi cells. Gain- and
loss-of-function experiments revealed a role for ALDH1A3 in cell
proliferation.
MATERIALS AND METHODS
Cell Isolation and Flow Cytometric Analysis
Human right atrial appendage specimens were obtained from
male and female patients (29–91 years old) who underwent
cardiac surgery for ischemic and/or valvular heart disease
through donation. The protocol received authorization from the
University Hospital Ethics Committee and the Cantonal Ethics
Committee Ethics Committee of Canton Vaud, Switzerland
on research involving humans. Informed, written consent
was obtained from the participants. In 3 patients (76–86
years old) who underwent left ventricular (LV) assist device
implantation, tissue specimens were obtained from the LV
apex. Immediately after their procurement, tissue specimens
were kept on ice, minced, and digested in a buffer containing
0.45 mg/ml collagenase from Clostridium histolyticum and
0.1 mg/ml proteinase bacterial Type XXIV (both from Sigma
Aldrich, St. Louis, MO, USA). Four rounds of enzymatic
digestion were used. Freshly isolated cells were immediately
reacted with Aldefluor (Stem Cell Technologies, Vancouver,
BC, Canada) to identify ALDHhi cells. Briefly, 2 × 106
cells/mL were suspended in Aldefluor assay buffer containing
the ALDH substrate BODIPYaminoacetaldehyde and incubated
at 37◦C for 45min. For each sample, cell aliquots were
incubated with or without 50mM diethylaminobenzaldehyde
(DEAB), an ALDH-specific inhibitor (36), and analyzed on
a Gallios flow cytometer (Beckman Coulter, Indianapolis, IN,
USA). The threshold used for the ALDHhi gate was 2.0%
of DEAB-treated control cells. Dead cells and cells in the
early-mid apoptosis were identified using DAPI and Annexin
V apoptosis detection kit-APC (eBioscience; Thermo Fisher
Scientific,Waltham,MA, USA), respectively. For flow cytometric
analyses of surface marker expression, 1 × 105 cells/tube were
incubated with Aldefluor and subsequently stained with marker-
specific antibodies (Supplementary Table 1) for 30min in the
dark. Fluorescence-activated cell sorting (FACS) based on ALDH
activity was performed on a MoFloAstrios cell sorter (Beckman
Coulter). To prevent cross-contamination between ALDHhi and
ALDHhi cells, sorting gates of these 2 populations were set up
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at least one log apart. The purity of sorted populations was
reanalyzed using ALDHhi and ALDHlo cells and was shown to
be greater than 95%. For expansion, cells were plated in gelatin-
coated 6-well plates and cultured in expansion medium (3:1
DMEM 1g/l glucose/Medium 199 [Invitrogen, Carlsbad, CA,
USA] supplemented with 10% horse serum [Serotec; BioRad
Labs., Hercules, CA, USA], 5% fetal calf serum (FCS) [Serotec],
100 U/ml penicillin [Invitrogen], and 100 mg/ml streptomycin
[Invitrogen]). Cells that remained in suspension after 24 h in
culture were discarded, and adherent cells were expanded. In
a subset of experiments, atrial appendage specimens were not
dissociated using enzymatic techniques, but cultured ex vivo
as primary tissue explants (37). Briefly, atrial tissue explants
were cut into small pieces (≈1mg) that were placed in gelatin-
coated culture dishes (Corning; Thermo Fisher Scientific) and
cultured in IMDM supplemented with 20% FCS, 100 U/ml
penicillin and 100 mg/ml streptomycin. After 10 days, the small
pieces of tissue were removed from culture dishes and the cell
populations that hadmigrated out of them (outgrowth cells) were
expanded.
Immunocytochemistry
Immunocytochemical staining was performed on cells
cultured in gelatin-coated wells using the antibodies listed
in Supplementary Table 2. Stained cells were mounted with
Vectashield mounting medium containing DAPI (Vector
Labs, Burlingame, CA, USA). Images were captured using an
Axiovision (Carl Zeiss Jena, Germany) fluorescence microscope
and a Nikon LSR Eclipse TE2000S inverted fluorescence
microscope (Nikon, Tokyo, Japan).
Clonogenicity and Cell Proliferation Assays
To assess clonogenicity, atrial cells were seeded at limit dilution
and single cells were identified under a light microscope. Clones
derived from single cells were counted at later time points. To
assess cell growth, cell numbers were counted at different time
points after plating. The effect of DEAB on proliferation was
assessed in outgrowth cells. Cell proliferation was measured
using Click-iT R© EdUAlexa Fluor R© 488 imaging kit (Invitrogen),
as per manufacturer’s instructions. Briefly, cells were incubated
with EdU (10µM final concentration) for 2 h in expansion
medium, fixed with paraformaldehyde 2%, permeabilized with
0.3% Triton, incubated with Alexafluor azide for 30min in the
dark, and mounted with Vectashield. EdU+ cells and total cells
were counted under a fluorescence microscope, and percentages
of EdU+ cells were calculated. Cell density was expressed using
a microscopic score (range: 0–4) assigned by two independent
investigators blind to experimental conditions. RA levels in
cells were measured using Human Retinoic Acid ELISA Kit
(MBS705877-96; ANAWA Biotrend, Wangen, Switzerland). The
ability of the RA receptor agonist all-trans RA to replace ALDH
in promoting cell growth was tested. Varying concentrations of
all-trans RA (Sigma) were added to explant outgrowths cultured
in the presence of 100µM DEAB, and cell density was assessed
under a light microscope.
RNA Isolation, Reverse Transcription, and
Real-Time PCR
Total RNA was extracted using RNeasy isolation kit (Qiagen
N V, Hilden, Germany). Reverse transcription was performed
with QuantiTect Whole Transcriptome Kit (Qiagen) for RNA
from freshly isolated cells, and with Verso cDNA Synthesis
Kit (Thermo Fisher) for RNA from culture-expanded cells.
For expression analyses of cardiac transcription factors,
pluripotency-associated genes and cardiac differentiation
markers, cDNA was used as a template for real-time PCR or
relative quantitative PCR (qPCR) using specific probes and
the ABI Prism 7500 Fast Real-Time PCR System (Applied
Biosystems; Thermo Fisher). For expression analyses of ALDH
isoforms, Fast SYBR R©Green Master Mix (Life Technologies;
Thermo Fisher) with gene-specific primers (Thermo Fisher;
Supplementary Table 3) were used. Each reaction was carried out
in triplicate. To calculate the relative expression levels, we used
the 2−11Ct-method. RPL27 mRNA was used as an endogenous
control. Experiments linked to differentiation were done with
Taqman probes using β2–microglobuline as a reference gene.
Western Blotting
Western blotting was performed on ALDHhi and ALDHlo sorted
cells using rabbit anti-human ALDH1A3 antibody (Ab 129815,
Abcam, Cambridge, UK).
Cardiomyogenic Differentiation
Atrial cells at culture-passage 2 were reacted with Aldefluor.
ALDHhi and ALDHlo populations were sorted. Two protocols
were used to induce cardiac differentiation. Using the first
protocol (no NOTCH modulation), differentiation was induced
by switching the cells to MEM alpha (Invitrogen) containing
2% horse serum, 1 mmol/l dexamethasone (Sigma-Aldrich),
50 mg/ml ascorbic acid (Sigma-Aldrich), 10 mmol/l b-
glycerophosphate (Sigma-Aldrich), 100 U/ml penicillin, and 100
mg/ml streptomycin (differentiation medium). Because cells
were spontaneously differentiating into smooth muscle cells
using this protocol, a recently developed protocol involving
sequential NOTCH activation and inhibition was applied (38).
Cells were cultured on immobilized Delta-like1 (DLL1) ligand
(R&D Systems, Minneapolis, MN, USA) during 24 h. After cell
re-suspension, NOTCH pathway was inhibited by the inhibitor
of gamma secretase, DAPT (Sigma-Aldrich). Cells were cultured
under those conditions for 3 weeks in differentiation medium,
and cells were then assessed for expression of cardiac-specific
(Myh6, Myh7) and smooth muscle (SM)-specific (Myh11) genes
using quantitative RT-PCR. Expression of cardiac-specific α-
actinin and troponin I (cTnI), as well as SM myosin heavy
chain (sm-MHC) was assessed immunocytochemically. Cells
positive for α-actinin or cTnI, or both markers, and total cells
were counted under the fluorescence microscope. Percentages of
positive cells were calculated.
siRNA Silencing
Small interfering RNA (siRNA) was used to knockdown ALDH
isoform expression in atrial cells. All siRNAs were obtained
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from Thermo Fisher. ALDHhi sorted cells seeded on 6 well-
plates (50.000 cells/well) were allowed to adhere overnight.
Transfection was performed with Lipofectamine RNAiMAX
(Invitrogen), as per manufacturer’s instructions. siALDH1A3was
tested at different concentrations. In subsequent experiments,
siRNA specific for ALDH isoforms 1A1, 1A2, 1A3, 2A, 4A1, 8A1
was used at the 10 nM concentration. Percentages of ALDHhi
cells were measured at 24 h post-transfection using the Aldefluor
assay. EdU was added to cells at 24 h post-transfection, and EdU
incorporation was assessed using Click-iT R© EdU Alexa Fluor R©
488 imaging kit.
ALDH1A1 and ALDH1A3 Overexpression
The retroviral vector pMSCVpuro with either ALDH1A1
or ALDH1A3 coding sequences inserted was described and
validated previously (32). A retroviral vector with no insert was
used to control for unspecific virus-related effects. ALDHlo sorted
cells were transduced with retroviral supernatants in 6-well plates
(50,000 cells/well), as described previously (32). Twenty-four
hours post-transduction, cells were passaged and seeded at≈50%
density. EdU was added to the cells 24 h later. Cell proliferation
was analyzed using Click-iT R© EdU Alexa Fluor R© 488 imaging
kit.
Statistics
The data are presented as mean ± S.D. Student t-test was used
to compare two normally distributed populations. The Mann-
Whithney U test was used for nonparametric comparisons of
two groups. Differences with probability values p < 0.05 were
considered statistically significant.
RESULTS
Identification of ALDHhi Cells
Freshly isolated, myocyte-depleted populations were isolated
based on ALDH activity using the Aldefluor assay. ALDHhi
gating was established by inhibiting ALDH activity using DEAB
(Figure 1A). Freshly isolated cells from right atrial appendages
contained an average of 21.5+ 12.4% ALDHhi cells (n= 86). In a
few LV apex specimens available (n = 3), ALDHhi cells averaged
12.3 ± 2.1% of total cells. This finding demonstrated that
the LV apex also contains ALDHhi cells; however, quantitative
comparisons of atrial and LV cells were not performed due
to the small LV sample size. A majority of ALDHhi atrial
cells (73.1 + 20.2%) expressed the primitive surface marker
CD34 (Figure 1B), which was confirmed immunocytochemically
(Figure 1C), but not CD45 (<5%). There was no significant
correlation between ALDHhi cell number and age (Figure 1D),
gender, or ischemic vs. heart valve disease (data not shown).
Because freshly isolated ALDHlo cells could not be expanded
ex vivo, we used ALDHlo outgrowth cells (37) in a subset of
experiments including direct comparisons with ALDHhi cells. In
addition, outgrowth cells are of translational interest, as they give
rise to cardiosphere-derived cells that have been tested clinically
in patients after myocardial infarction (39). Representative gating
sequences from FACS experiments with different populations,
namely freshly isolated atrial cells, freshly isolated LV cells,
expanded atrial cells, and outgrowth cells are shown in Figure 1E.
In freshly isolated cells, but not in expanded ones and outgrowth
cells, ALDHhi and ALDHlo cells were visualized as discrete
populations, and the Aldefluor signal was incompletely inhibited
by DEAB. By contrast, the Aldefluor signal was fully suppressed
by DEAB in both expanded and outgrowth cells. These results
suggest that ALDH activity in freshly isolated cells may be higher
than in expanded and outgrowth cells. The frequency of ALDHhi
cells within the outgrowth population was stable during 3 weeks
but decreased thereafter (Figure 1F), suggesting that the pool of
ALDHhi cells within cultured tissue explants may be exhausted at
late time points.
Freshly Isolated ALDHhi Cells Express
CD34 Along With Mesenchymal and
Endothelial Markers
Differential surface marker expression in ALDHhi and ALDHlo
atrial cells has not been analyzed previously. Freshly isolated
ALDHhi cells (Figure 2A) expressed the primitive marker
CD34, platelet endothelial cell adhesion molecule-1 (PECAM-
1)/CD31, and endoglin/CD105, a marker expressed by both
endothelial and stromal progenitor cells. Thus, the ALDHhi
population appeared to include both mesenchymal progenitors
and differentiating endothelial progenitors. The ALDHhi
population was enriched with cells expressing vascular cell
adhesion molecule-1 (VCAM-1)/CD106 (38-fold increase).
Small cell subsets expressed the common leukocyte antigen
CD45 (<5%) and stem cell markers c-kit/CD117 (1.2 ± 0.9%)
and prominin/CD133 (2.3 ± 3.1%). ALDHhi outgrowth cells
lacked CD34 expression. Their surface marker profile did not
significantly differ from that of ALDHlo cells (Figure 2B).
Differential Expression of Pluripotency
Genes and Markers for Cardiac Lineages
We analyzed expression of pluripotency-associated genes and
cardiac-specific markers as evidence of presence of primitive
cells and cardiac progenitor cells, respectively, in atrial
cell populations. Freshly isolated ALDHhi cells expressed
pluripotency-associated genes (Oct4, Nanog) and cardiac-
specific transcription factors (Nkx2.5, Mef2c, GATA4, Tbx5)
at higher levels (3–5 orders of magnitude) than did ALDHlo
cells (Figure 3A). Nkx2.5, GATA4, and Mef2c expression was
confirmed immunocytochemically (Figure 3C). Similar albeit
weaker differences (1–2 orders of magnitude) were found
between ALDHhi and ALDHlo outgrowth cells (Figure 3B).
These results suggest that the freshly isolated ALDHhi population
may be enriched with primitive cells and cells committed to a
cardiac fate.
Freshly Isolated ALDHhi Cells Are
Clonogenic and Selectively Expandable
Freshly isolated ALDHhi cells selectively formed clones and
could be expanded ex vivo. In principle, this might be due
to selective resistance to apoptosis induced by the isolation
procedure. After DAPI exclusion, virtually no ALDHhi cells
but part of the ALDHlo population were Annexin V-positive
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FIGURE 1 | Flow cytometry analysis of ALDHhi atrial cells. (A) Freshly isolated cells. ALDHhi gating was established by inhibiting ALDH activity in Aldefluor-reacted
cells with DEAB. Left panels: ALDH/side scatter (SSC-A) plots. Right panels: ALDH/forward scatter (FSC-A) plots. (B) Freshly isolated cells. Aldefluor activity and
CD34 expression. (C) CD34 immunostaining (red); ALDH (green); staining with istotype-matched control antibody is shown. (D) ALDHhi cells (%) did not correlate with
age. (E) FACS plots of different populations (top to bottom: freshly isolated atrial cells, freshly isolated LV cells, expanded atrial cells, atrial outgrowth cells). Gating
sequences are shown. R1-gated cells in FSC-A/SSC-A plots are gated for homogeneity (R2, R3) and DAPI exclusion (R4). R5 and R7 gates define ALDHlo and
ALDHhi cells, respectively. To prevent cross-contamination between ALDHhi and ALDHhi cells, R5 and R7 gates were set one log apart (i.e., R6-gated cells were
discarded). (F) Percentages of ALDHhi outgrowth cells after 1–4 weeks of ex vivo tissue culture.
(Figure 4A) suggesting they were in the early-mid apoptosis.
The clonogenicity index was 0.27 ± 0.09% in ALDHhi cells,
0% in ALDHlo cells, and 0.03 ± 0.01% in the bulk (unsorted)
population (Figure 4B). Freshly isolated ALDHhi cells grew faster
than the bulk population. Similarly, ALDHhi outgrowth cells
grew faster than ALDHlo ones (Figure 4C). Expanded ALDHhi
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FIGURE 2 | Flow cytometry analyses of cell-surface marker expression in ALDHhi and ALDHlo atrial cells. (A) Freshly isolated cells. Aldefluor-reacted cells were
stained with antibodies to the indicated markers (see Supplementary Table 1). CD31+, CD105+, CD34+, and CD106+ cells (%) are significantly increased in ALDHhi
cells relative to ALDHlo cells (fold-increases are indicated); *p < 0.05. (B) Outgrowth cells. ALDHhi cells lack CD34 expression and exhibit a marker profile similar to
that of ALDHlo cells (n ≥ 5 per marker and group).
cells lost ALDH activity over time (e.g., the frequency of ALDHhi
cells in the progeny of freshly isolated ALDHhi cells after 13
culture-passages was 32%). These observations suggest that high
ALDH activitymay be required for the initial survival and growth
of freshly isolated cells, but not in established cell cultures,
reflecting cell adaptation to in vitro conditions.
All-Trans RA Reverses DEAB-Mediated
Cell Growth Suppression
To assess the effect of ALDH on cell growth, explant outgrowths
were cultured with or without DEAB at varying concentrations.
DEAB reduced proliferation in outgrowth cells in a dose-
dependent manner (Figure 4D), as determined using an EdU
incorporation assay. Because ALDH1 naturally synthesizes RA,
we measured RA concentrations in ALDHhi and ALDHlo cells.
Not surprisingly, we found higher RA levels in the former
(Figure 4E). We then tested the ability of all-trans RA to replace
ALDH in promoting cell growth. all-trans RA (10µM) reversed
cell growth suppression mediated by DEAB (Figure 4F). These
results suggest that ALDH might promote atrial cell growth
through RA, at least in part.
ALDHhi Cells Have Higher Propensity to
Produce Mature Cardiomyocytes Than
ALDHlo Cells
Having shown that the ALDHhi population is enriched
with stem/progenitor cells, we addressed its cardiomyogenic
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FIGURE 3 | Expression of pluripotency-associated genes (Oct4, Nanog) and cardiac-specific transcription factors (Nkx2.5, Mef2c, GATA4, Tbx5). (A) Quantitative
RT-PCR analyses of freshly isolated atrial cells (n = 5/group). (B) Outgrowth cells (n = 5/group). 2−11Ct values for ALDHhi vs. ALDHlo cells are shown. (C). Freshly
isolated ALDHhi cells. Immunostaining for Nkx2.5 (red), GATA4 (green), and Mef2c (green); DAPI nuclear counterstaining (blue). Nkx2.5/GATA4 and Nkx2.5/Mef2c
double stainings are shown.
potential. Two differentiation protocols, with or without Notch
modulation, were used. Under differentiation conditions with no
Notch-modulation, both ALDHhi and ALDHlo cells expressed
marked levels of MYH11 gene, while the cardiomyocyte
markers MYH6 and MYH7 were not induced (Figure 5A). Both
populations massively differentiated into smooth muscle cells,
as illustrated by smMHC immunostaining; less than 2% of
cells stained positive for cardiomyocyte-specificmarker α-actinin
(Figure 5B). By contrast, under Notch-modulated conditions
both ALDHlo and ALDHhi cells expressed significant levels of
cardiomyocyte-specific MYH6 and MYH7 (Figure 5A) and α-
actinin (Figures 5B,D). Cardiac troponin-I (TNNI) was also
identified in differentiated cells. Interestingly, under Notch-
modulated conditions MYH6 and MYH7 gene expression was
more pronounced in ALDHhi than ALDHlo cells. Similarly, the
number of α-actinin/TNNI double positive cells derived from
ALDHhi cells was significantly higher than that derived from
ALDHlo cells (Figures 5C,D). These results indicated that the
differentiated ALDHhi cells were more terminally differentiated
than ALDHlo cells, consistent with a higher propensity of
ALDHhi cells to differentiate into cardiomyocytes.
ALDH1A3 Is the Most Highly Expressed
ALDH Isoform in Atrial Cells
The specific ALDH isoforms expressed in ALDHhi atrial cells
have not been identified previously. We therefore analyzed the
ALDH isoform expression profiles of ALDHhi and ALDHlo
cells. ALDH1A3 was the most highly expressed isoform in
freshly isolated ALDHhi cells, as well as the most highly
overexpressed isoform in ALDHhi relative to ALDHlo cells (≈8-
fold increase; Figure 6A). ALDH1A3 protein levels in ALDHhi
cells were higher than in ALDHlo cells, as evidenced by Western
blot analysis (Figure 6B). Similar findings were observed in
outgrowth cells (≈6-fold increase in ALDH1A3 mRNA levels in
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FIGURE 4 | Cell viability, clonogenicity, cell growth, intracellular RA levels, effects of DEAB and all-trans RA. (A) Freshly isolated cells. Flow cytometry analysis of DAPI,
Aldefluor (with and without DEAB), and Annexin V (right panel). Part of ALDHlo cells are Annexin V-positive (K-+). (B) Freshly isolated ALDHhi cells and unsorted cells.
Clonogenic analysis (n = 3/group). (C) In vitro growth kinetics. Left panel: freshly isolated cells; right panel: outgrowth cells (n = 3/group in both panels).
(D) Dose-dependent effects of DEAB on EdU incorporation and cell density. (E) RA concentrations in ALDHhi and ALDHlo cells measured by ELISA.
(F) Dose-dependent effects of all-trans RA (ATRA) on cell density in the presence of DEAB (100µM).
ALDHhi vs. ALDHlo cells; Figure 6C). For comparison, a subset
of 10 ALDH isoforms selected based on published data (40) were
measured in atrial total tissue, and ALDH2 was found to be the
most highly expressed isoform (Figure 6D). Thus, ALDH1A3 is
the key isoform expressed in ALDHhi atrial cells.
ALDH1A3 siRNA Reduces ALDH Activity
and in Vitro Cell Proliferation
To address the contributions of individual ALDH isoforms
to ALDH activity in ALDHhi cells, we examined whether
altering their expression levels would affect ALDH activity.
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FIGURE 5 | Cardiac differentiation of ALDHhi and ALDHlo atrial cells using a Notch modulation-based protocol. (A) real-time RT-PCR expression analyses of
cardiac-specific (Myh6, Myh7) and smooth muscle-specific genes (Myh11) under expansion (Exp) and differentiation conditions, with or without Notch modulation.
2−1Ctvalues are shown. One example of two independent experiments performed in triplicates is shown; *p < 0.05 vs. cells in expansion or between the indicated
conditions. (B) Immunostaining of ALDHhi and ALDHlo cells for smooth musche-myosin heavy chain (smMHC) and cardiac-specific α-actinin, with or without Notch
modulation. (C) Immunostaining of ALDHhi and ALDHlo cells for cardiac-specific α-actinin and troponin I (cTNNI) under Notch-modulated conditions. (D) Quantitative
analyses of smMHC, α-actinin, and α-actinin/cTNNI positive cells; *p < 0.05 vs. cells in expansion (a minimum of 2000 cells in 30 different fields at 40x magnification
were analyzed for quantification).
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FIGURE 6 | RT-PCR analysis of ALDH isoform gene expression in different populations. (A) ALDHhi cells isolated using enzymatic techniques. Upper panel: ALDH
isoform expression (2−1Ct values; n = 4 patients). Lower panel: Relative expression in ALDHhi vs. ALDHlo cells (2−11Ct values; n = 4). (B) Western blot showing
ALDH1A3 protein expression in unsorted, ALDHhi and ALDHlo atrial cells. (C) Outgrowth cells. Relative expression in ALDHhi vs. ALDHlo cells is shown (n = 3).
(D) Total atrial tissue (2−1Ct values; n = 3). ND, not determined (2−11Ct values that could not be calculated).
Isoform-specific siRNAs were transfected into ALDHhi sorted
cells, which were then analyzed using the Aldefluor assay.
siALDH1A3 reduced the percentage of ALDHhi cells in a
dose-dependent manner up to ≈90% (Figures 7A,B). On the
other hand, siALDH1A1, siALDH1A2, siALDH2A, siALDH4A1,
and siALDH8A1 (10 nM) did not significantly affect percentages
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FIGURE 7 | ALDH isoform-specific loss- and gain-of-function studies. (A) Flow cytometry plots of ALDHhi sorted, Aldefluor-reacted cells (with or w/o DEAB) after
siALDH1A3 transfection or mock transfection (no siRNA). (B) siALDH1A3 dose-response study. ALDHhi cell numbers after siALDH1A3 transfection using the indicated
concentrations relative no siRNA. (C) ALDHhi cell numbers after siALDH-isoform-specific transfection (10 nM) relative to no siRNA). (D) EdU+ cell numbers (%) after
(Continued)
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FIGURE 7 | siALDH1A3 transfection (10 nM) relative no siRNA. (E) Flow cytometry plots of ALDHlo sorted, Aldefluor-reacted cells (with or w/o DEAB) transduced with
pMSCVpuro-ALDH1A1 or pMSCVpuro-ALDH1A3 retroviral vectors, or control vector with no insert (pMSCVpuro). (F) ALDHhi cell numbers after transduction with
pMSCVpuro-ALDH1A1 or pMSCVpuro-ALDH1A3 relative to control vector. (G) EdU+ cell numbers (%) after transduction with pMSCVpuro-ALDH1A1 or
pMSCVpuro-ALDH1A3 relative to control vector; *p < 0.05.
of ALDHhi cells (Figure 7C). To address the role of ALDH1A3
in cell proliferation, siALDH1A3 (10 nM) was transfected into
ALDHhi sorted cells and proliferation was assessed using EdU
incorporation kit. siALDH1A3 reduced the number of EdU+
cells by≈40% (Figure 7D).
ALDH1A3 Overexpression Increases
in Vitro Cell Proliferation
Having shown that ALDH1A3 knockdown inhibits ALDHhi cell
proliferation, we overexpressed this isoform in ALDHlo cells.
Retrovirus-mediated ALDH1A3 gene transduction into ALDHlo
sorted cells enhanced both ALDH activity (Figures 7E,F) and
cell proliferation (Figure 7G) compared with cells infected with
control retrovirus with no insert. ALDH1A1 gene transduction
also induced a minor increase in Aldefluor-positive cells.
Collectively, these results indicate that ALDH1A3 promotes in
vitro proliferation of atrial-derived cells.
DISCUSSION
We and others have shown previously that high ALDH
activity defines a human cardiac atrial appendage cell
population enriched with stem and progenitor cells that
have cardiomyogenic potential (33, 35). ALDHhi activity
coincides with primitive surface marker (CD34+) as well as
mesenchymal and endothelial progenitor marker expression.
Regarding the co-expression of CD34 and CD31, CD34+
endothelial progenitor-like cells have been described previously
(41). Interestingly, the ALDHhi population is significantly
enriched with VCAM1+ cells. Moreover, ALDHhi cells
differentially express both pluripotency genes and markers
for more established cardiac lineages including Nkx2.5,
consistent with them being enriched with both primitive cells
and cells committed to a cardiac fate. VCAM1+Nkx2.5+
cells have been identified previously as a discrete lineage of
myocardial committed cells during early human cardiovascular
development (42). These findings raise the question as to
whether the VCAM1+Nkx2.5+ subset of the adult ALDHhi atrial
population consists of myocardial committed progenitor cells.
These results suggest that ALDHhi atrial cells may be enriched
with cells that have cardiomyogenic potential. To address
this aspect, we used a novel differentiation protocol based on
Notch modulation (38). Compared with ALDHlo cells, ALDHhi
cells produced higher numbers of mature cardiomyocytes, as
evidenced by higher expression levels of cardiac specific genes
(MYH6, MYH7) and higher frequencies of cardiac-specific
α-actinin/troponin I double-positive cells. These results indicate
that the ALDHhi population is enriched with cardiac progenitor
cells. In vivo lineage tracing studies addressing the role of
ALDHhi cardiac cells are still needed.
Freshly isolated ALDHhi cells, but not ALDHlo cells, include
a subset of clonogenic cells and can be expanded. Annexin V-
staining suggests that ALDHhi cells may be more apoptosis-
resistant than ALDHlo ones. Higher apoptosis-resistance of
ALDHhi vs. ALDHlo cells has been reported in various cancer
stem cells (43–45). Silencing ALDH1A by siRNA or shRNA
in human melanoma cancer stem cells led to cell cycle arrest,
apoptosis and decreased cell viability in vitro and reduced
tumorigenesis in vivo (45). In our study, the theoretical possibility
that low ALDH activity in a majority of freshly isolated cells is
a result of apoptosis, rather than its cause, cannot be ruled out.
Nevertheless, DAPI/Annexin-V double-negative ALDHlo cells
that were not in the early-mid apoptosis still failed to grow in
vitro, suggesting that high ALDH activity might be required in
the initial cell culture stages. On the other hand, both the ALDHlo
subset of the ALDHhi progeny (i.e., ALDHhi cells having lost their
ALDH activity over time in vitro) and ALDHlo outgrowth cells
could be expanded, albeit with slower growth kinetics compared
with ALDHhi cells. This observation suggests that high ALDH
activity may not be required in established cell cultures possibly
due to cell adaptation mechanisms.
ALDH isoform expression analysis identified ALDH1A3 as
both the most highly expressed isoform in ALDHhi atrial
cells and the main differentially expressed isoform in ALDHhi
vs. ALDHlo cells. Similar results were found in both freshly
isolated and outgrowth cells. Moreover, ALDHhi cells showed
higher ALDH1A3 protein levels than ALDHlo cells. siALDH1A3
transfected into ALDHhi cells reduced the number of cells
that remained ALDHhi by ≈90%, whereas knocking down
ALDH1A1, ALDH1A2, ALDH2A, ALDH4A1, or ALDH8A1 did
not significantly affect it. These findings establish ALDH1A3
as the key isoform responsible for ALDH activity in ALDHhi
cells. siALDH1A3 transfected into ALDHhi cells reduced their
proliferation. Specific ALDH inhibition by DEAB likewise
suppressed cell proliferation. Conversely, retrovirus-mediated
ALDH1A3 gene transduction into ALDHlo cells promoted it.
ALDH1A1 overexpression induced a similar albeit weaker effect,
suggesting that exogenous ALDH1A1 may replace the naturally
expressed ALDH1A3 isoform in this respect.
ALDH1A is the rate-limiting factor in the production of
RA (16–18). We found higher RA levels in ALDHhi atrial cells
than in ALDHlo cells. Moreover, the RA receptor agonist, all-
trans RA, replaced ALDH in promoting atrial cell growth in
the presence of DEAB. In breast cancer cell lines, ALDH1A3
influenced cancer progression via differential RA signaling (44).
In human melanoma cancer stem cells, ALDH1A contributed to
the stemness through RA-dependent and -independent pathways
(45). In HSCs, all-trans RA reversed DEAB-mediated effects on
cell expansion and differentiation, suggesting that the ability of
ALDH to generate RA is important in determining HSC fate (13).
Of note, the catalytic activity of ALDH1A3 for all-trans retinal
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may be 10-fold higher than that of ALDH1A1 (46). Moreover,
ALDH1A3 is transcriptionally activated by all-transRA in human
epidermal keratinocytes, which raises the theoretical possibility
of a positive feedback loop between ALDH1A3 and RA in some
cell types (47). Our results are consistent with, but do not firmly
establish, RA-dependent ALDH effects on atrial cell growth.
Functional roles of ALDH1A3 in stem/progenitor cells are
poorly understood. ALDH1A3 promotes neural progenitor cell
self-renewal through the regulation of ALDH1A3 pre-mRNA
3′-end processing by RNA-binding protein Sam68 (Khdrbs1).
Decreases in ALDH1A3 expression and activity resulted in
decreased clonogenicity and reduced the pool of proliferating
neural progenitor cells (48). Several studies showed that
ALDH1A3 is a cancer stem cell gene. ALDH1A3 expression was
detected in 78% of small-sized Ki-67+ proliferating progenitor
cells in the human breast cancer cell line HCC1937 (43). Most
recently, ALDH1A3 was shown to affect colon cancer in vitro
proliferation and invasion depending on CXCR4 status (49).
In neuroblastoma cell lines expressing high ALDH1A3 levels,
ALDH1A3 knockout via CRISPR/Cas9 gene editing reduced
clonogenicity and mediated cell type-dependent inhibition of
self-renewal properties of tumor inducing cells (50). Collectively,
these findings indicate that ALDH1A3 play functional roles in
both normal and cancer stem/progenitor cells.
In conclusion, our results suggest that the ALDHhi population
isolated from human cardiac atrial appendages may be enriched
with stem/progenitor cells showing cardiomyogenic potential,
and that ALDH1A3 is the key ALDH isoform responsible for
ALDH activity in these cells, affecting their in vitro proliferation.
AUTHOR CONTRIBUTIONS
Substantial contributions to the conception or design of the work
(GV and SP) or the acquisition, analysis, or interpretation of
data for the work (SP, IP, LB, EC, GM, PM, TP, GV), Drafting
the work or revising it critically for important intellectual
content (SP, IP, GV), Final approval of the version to be
published, Agreement to be accountable for all aspects of
the work in ensuring that questions related to the accuracy
or integrity of any part of the work are appropriately
investigated and resolved (SP, IP, LB, EC, GM, PM, TP,
GV).
FUNDING
This study was supported by grants by the Swiss National Science
Foundation (310030_140485), the Swiss Heart Foundation,
and the Fondation Vaudoise de Cardiologie (Lausanne) to
GV.
ACKNOWLEDGMENTS
Albert Spicher, Ph.D., carried out the initial characterization
of ALDHhi cells and initial ALDH isoform expression
analyses. Ludwig von Segesser, M.D., Piergiorgio Tozzi,
M.D., Matthias Kirsch, M.D., Enrico Ferrari, M.D., Patrick
Ruchat, M.D., Javier Orrit, M.D., Lars Niclauss, M.D.,
Philipp Gersbach, M.D., and Dominique Delay, M.D.,
procured heart tissue specimens from patients undergoing
heart surgery. Sara Bolis, R.A., Sintia Winkler, Ph.D., and
Andreia Marques Ribeiro, Ph.D., provided expert assistance
in cell sorting. Darko Maric, Ph.D., and Andrée Porret
provided expert assistance in retrovirus production and siRNA
transfection.
SUPPLEMENTARY MATERIAL




1. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review:
evidence for CD34 as a common marker for diverse progenitors. Stem Cells
(2014) 32:1380–9. doi: 10.1002/stem.1661
2. Tateishi K, Ashihara E, Takehara N, Nomura T, Honsho
S, Nakagami T, et al. Clonally amplified cardiac stem cells
are regulated by Sca-1 signaling for efficient cardiovascular
regeneration. J Cell Sci. (2007) 120:1791–800. doi: 10.1242/jcs.
006122
3. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al.
Adult cardiac stem cells aremultipotent and support myocardial regeneration.
Cell (2003) 114:763–76.
4. Vicinanza C, Aquila I, Scalise M, Cristiano F, Marino F, Cianflone E, et
al. Adult cardiac stem cells are multipotent and robustly myogenic: c-kit
expression is necessary but not sufficient for their identification. Cell Death
Differ. (2017) 24:2101–16. doi: 10.1038/cdd.2017.130
5. Cai J, Weiss ML, Rao MS. In search of “stemness”. Exp Hematol. (2004)
32:585–98. doi: 10.1016/j.exphem.2004.03.013
6. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr
Stem Cell Res Ther. (2008) 3:237–46. doi: 10.2174/157488808786
734006
7. Balber AE. Concise review: aldehyde dehydrogenase bright stem and
progenitor cell populations from normal tissues: characteristics, activities,
and emerging uses in regenerative medicine. Stem Cells (2011) 29:570–5.
doi: 10.1002/stem.613
8. Xu X, Chai S, Wang P, Zhang C, Yang Y, Wang K. Aldehyde
dehydrogenases and cancer stem cells. Cancer Lett (2015) 369:50–7.
doi: 10.1016/j.canlet.2015.08.018
9. Laird DJ, De Tomaso AW, Weissman IL. Stem cells are units of natural
selection in a colonial ascidian. Cell (2005) 123:1351–60. Erratum in: Cell
(2006) 124:647–8. doi: 10.1016/j.cell.2005.10.026
10. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, et
al. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum
Genomics (2011) 5:283–303. doi: 10.1186/1479-7364-5-4-283
11. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing
enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab
Toxicol. (2008) 4:697–720. doi: 10.1517/17425255.4.6.697
12. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J. Direct
demonstration of elevated aldehyde dehydrogenase in human hematopoietic
progenitor cells. Blood (1990) 74:1945–50.
13. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ,
et al. Inhibition of aldehyde dehydrogenase and retinoid signaling
induces the expansion of human hematopoietic stem cells. Proc
Frontiers in Cardiovascular Medicine | www.frontiersin.org 13 July 2018 | Volume 5 | Article 90
Puttini et al. ALDH1A3 and Cardiac Progenitor Cells
Natl Acad Sci USA (2006) 103:11707–12. doi: 10.1073/pnas.06038
06103
14. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Del Bo R, Crimi M, et al.
Transplanted ALDHhiSSClo neural stem cells generate motor neurons and
delay disease progression of nmd mice, an animal model of SMARD1. Hum
Mol Genet (2006) 15:167–87. doi: 10.1093/hmg/ddi446
15. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide resistant
L1210 leukemia. Cancer Res. (1984) 445:156.
16. Zhao D, McCaffery P, Ivins KJ, Neve RL, Hogan P, Chin WW, et al. Molecular
identification of a major retinoic-acid-synthesizing enzyme, a retinaldehyde-
specific dehydrogenase. Eur J Biochem (1996) 240:15–22.
17. Elizondo G, Corchero J, Sterneck E, Gonzalez FJ. Feedback inhibition
of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid
through retinoic acid receptor alpha and CCAAT/enhancer-binding
protein beta. J Biolog Chem. (2000) 275:39747–353. doi: 10.1074/jbc.M00
4987200
18. Black W, Vasiliou V. The aldehyde dehydrogenase gene superfamily
resource center. Hum Genomics (2009) 136:e142. doi: 10.1186/1479-7364-4-
2-136
19. Collins SJ. Retinoic acid receptors, hematopoiesis and leukemogenesis.
Curr Opin Hematol. (2008) 15:346–51. doi: 10.1097/MOH.0b013e32
83007edf
20. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde
dehydrogenase: its role as a cancer stem cell marker comes down to
the specific isoform. Cell Cycle (2011) 10:1378–84. doi: 10.4161/cc.10.9.
15486
21. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M,
et al. ALDH1 is a marker of normal and malignant human mammary stem
cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 1:555–67.
doi: 10.1016/j.stem.2007.08.014
22. Burger PE, Gupta R, Xiong X, Ontiveros CS, Salm SN, Moscatelli D,
et al. High aldehyde dehydrogenase activity: a novel functional marker
of murine prostate stem/progenitor cells. Stem Cells (2009) 27:2220–8.
doi: 10.1002/stem.135
23. Marcato P, Dean C, Pan D, Araslanova R, Gillis M, Joshi M, et al. Aldehyde
dehydrogenase activity of breast cancer stem cells is primarily due to isoform
ALDH1A3 and its expression is predictive of metastasis. Stem Cells (2011)
29:32–45. doi: 10.1002/stem.563
24. Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W,
Jimeno A, et al. ALDH1B1 is crucial for colon tumorigenesis
by modulating Wnt/beta-Catenin, notch and PI3K/Akt signaling
pathways. PLoS ONE (2015) 10:e0121648. doi: 10.1371/journal.pone.
0121648
25. Yan J, De Melo J, Cutz JC, Aziz T, Tang D. Aldehyde dehydrogenase 3A1
associates with prostate tumorigenesis. Br J Cancer (2014) 110:2593–603.
doi: 10.1038/bjc.2014.201
26. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Luderman S, et
al. Isolation of primitive human hematopoietic progenitors on the basis of
aldehyde dehydrogenase activity. Proc Natl Acad Sci USA. (1999) 96:9118–23.
27. Gunduz E, Demirel G, Bal C, Gulbas Z. Evaluation of mobilized peripheral
stem cells according to CD34 and aldehyde dehydrogenase expression and
effect of SSC(lo) ALDH(br) cells on hematopoietic recovery. Cytotherapy
(2010) 12:1006–12. doi: 10.3109/14653249.2010.509393
28. Shoulars K, Noldner P, Troy JD, Cheatham L, Parrish A,
Gentry T, et al. Development and validation of a rapid,
aldehyde dehydrogenase bright-based cord blood potency
assay. Blood (2016) 127:2346–54. doi: 10.1182/blood-2015-08-
666990
29. Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Hohm SA, Neelamkavil
MJ, et al. Revascularization of ischemic limbs after transplantation of human
bone marrow cells with high aldehyde dehydrogenase activity. Blood (2009)
113:5340–51. doi: 10.1182/blood-2008-04-154567
30. Sondergaard CS, Hess DA, Maxwell DJ, Weinheimer C, Rosová I, Creer
MH, et al. Human cord blood progenitors with high aldehyde dehydrogenase
activity improve vascular density in a model of acute myocardial infarction. J
Transl Med. (2010) 8:24. doi: 10.1186/1479-5876-8-24
31. Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang
PC, et al. Cardiovascular cell therapy research network (CCTRN).
Evaluation of cell therapy on exercise performance and limb perfusion
in peripheral artery disease: The CCTRN PACE Trial (Patients
with intermittent claudication injected with ALDH bright cells).
Circulation (2017) 135:1417–28. doi: 10.1161/CIRCULATIONAHA.116.
025707
32. Perin EC, Silva GV, Zheng Y, Gahremanpour A, Canales J, Patel
D, et al. Randomized, double-blind pilot study of transendocardial
injection of autologous aldehyde dehydrogenase-bright stem cells in
patients with ischemic heart failure. Am Heart J (2012) 163:415–21.
doi: 10.1016/j.ahj.2011.11.020
33. Spicher A, Meinhardt A, Roehrich ME, Vassalli G. Phenotypic
characterization of murine and human cardiac-resident progenitor
cells isolated on basis of aldehyde-dehydrogenase activity. Circulation
(2007) 116:II−167-II−168.
34. Roehrich ME, Spicher A, Milano G, Vassalli G. Characterization of cardiac-
resident progenitor cells expressing high aldehyde dehydrogenase activity.
Biomed Res Int. (2013) 2013:503047. doi: 10.1155/2013/503047
35. Koninckx R, Daniëls A, Windmolders S, Mees U, Macianskiene R,
Mubagwa K, et al. The cardiac atrial appendage stem cell: a new and
promising candidate for myocardial repair. Cardiovasc Res. (2013) 97:413–23.
doi: 10.1093/cvr/cvs427
36. Morgan CA, Parajuli B, Buchman CD, Dria K, Hurley TD. N,N-
diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based
inhibitor for humanALDH isoenzymes.ChemBiol Interact. (2015) 234:18–28.
doi: 10.1016/j.cbi.2014.12.008
37. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F,
et al. Isolation and expansion of adult cardiac stem cells from human and
murine heart. Circ Res. (2004) 95:911–21. doi: 10.1161/01.RES.0000147315.
71699.51
38. Plaisance I, Perruchoud S, Fernandez-Tenorio M, Gonzales C, Ounzain
S, Ruchat P, et al. Cardiomyocyte lineage specification in adult human
cardiac precursor cells via modulation of enhancer-associated long noncoding
RNA expression. J Am Coll Cardiol Basic Trans Sci. (2016) 1:472–93.
doi: 10.1016/j.jacbts.2016.06.008
39. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D,
et al. Intracoronary cardiosphere-derived cells for heart regeneration after
myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.
Lancet (2012) 379:895–904. doi: 10.1016/S0140-6736(12)60195-0
40. Alnouti Y, Klaassen CD. Tissue distribution, ontogeny, and regulation
of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical
microsomal enzyme inducers in mice. Tox Sci. (2008) 101:51–64.
doi: 10.1093/toxsci/kfm280
41. Ferreras C, Cole CL, Urban K, Jayson GC, Avizienyte E. Segregation of
late outgrowth endothelial cells into functional endothelial CD34- and
progenitor-like CD34+ cell populations. Angiogenesis (2015) 18:47–68.
doi: 10.1007/s10456-014-9446-1
42. Skelton RJP, Costa M, Anderson DJ, Bruveris F, Finnin BW, Koutsis
K, et al. SIRPA, VCAM1 and CD34 identify discrete lineages during
early human cardiovascular development. Stem Cell Res. (2014) 13:172–9.
doi: 10.1016/j.scr.2014.04.016
43. Kashii-Magaribuchi K, Takeuchi R, Haisa Y, Sakamoto A, Itoh A, Izawa Y, et
al. Induced expression of cancer stem cell markers ALDH1A3 and Sox-2 in
hierarchical reconstitution of apoptosis-resistant human breast cancer cells.
Acta Histochem Cytochem. (2016) 49:149–58. doi: 10.1267/ahc.16031
44. Marcato P, Dean CA, Liu RZ, Coyle KM, Bydoun M, Wallace M, et
al. Aldehyde dehydrogenase 1A3 influences breast cancer progression
via differential retinoic acid signaling. Mol Oncol. (2015) 9:17–31.
doi: 10.1016/j.molonc.2014.07.010
45. Luo Y, Dallaglio K, Chenc Y, RobinsonWA, Robinson SE, McCarter MD, et al.
ALDH1A isozymes are markers of human melanoma stem cells and potential
therapeutic targets. Stem Cells (2012) 30:2100–13. doi: 10.1002/stem.1193
46. Sima A, Parisotto M, Mader S, Bhat PV. Kinetic characterization of
recombinant mouse retinal dehydrogenase types 3 and 4 for retinal substrates.
Biochim Biophys Acta (2009) 1790:1660–4. doi: 10.1016/j.bbagen.2009.09.004
47. Koenig U, Amatschek S, Mildner M, Eckhart L, Tschachler E. Aldehyde
dehydrogenase 1A3 is transcriptionally activated by all-trans-retinoic acid
in human epidermal keratinocytes. Biochem Biophys Res Commun. (2010)
400:207–11. doi: 10.1016/j.bbrc.2010.08.035
Frontiers in Cardiovascular Medicine | www.frontiersin.org 14 July 2018 | Volume 5 | Article 90
Puttini et al. ALDH1A3 and Cardiac Progenitor Cells
48. La Rosa P, Bielli P, Compagnucci C, Cesari E, Volpe E, Farioli Vecchioli S, et
al. Sam68 promotes self-renewal and glycolytic metabolism in mouse neural
progenitor cells by modulating Aldh1a3 pre-mRNA 3′-end processing. Elife
(2016) 5:e20750. doi: 10.7554/eLife.20750
49. Feng H, Liu Y, Bian X, Zhou F, Liu Y. ALDH1A3 affects colon cancer in
vitro proliferation and invasion depending on CXCR4 status. Br Cancer (2018)
118:224–32. doi: 10.1038/bjc.2017.363
50. Flahaut M, Jauquier N, Chevalier N, Nardou K, Balmas Bourloud K,
Joseph JM, et al. Aldehyde dehydrogenase activity plays a key role in
the aggressive phenotype of neuroblastoma. BMC Cancer (2016) 16:781.
doi: 10.1186/s12885-016-2820-1
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Puttini, Plaisance, Barile, Cervio, Milano, Marcato, Pedrazzini
and Vassalli. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 15 July 2018 | Volume 5 | Article 90
